During the last session, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)’s traded shares were 1,552,651, with the beta value of the company hitting 1.06. At the end of the trading day, the stock’s price was $1.51, reflecting an intraday loss of -3.21% or -$0.05. The 52-week high for the ACRX share is $2.94, that puts it down -94.7% from that peak though still a striking +33.11% gain since the share price plummeted to a 52-week low of $1.01. The company’s market capitalization is $179.61 Million, and the average intraday trading volume over the past 10 days was 1.77 Million shares, and the average trade volume was 6.34 Million shares over the past three months.
AcelRx Pharmaceuticals, Inc. (ACRX) received a consensus recommendation of Overweight from analysts. That translates to a mean rating of 2.2. ACRX has a Sell rating from 1 analyst(s) out of 4 analysts who have looked at this stock. Neither of the analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 3 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.08.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX): Trading Information
AcelRx Pharmaceuticals, Inc. (ACRX) registered a -3.21% downside in the last session and has traded in the red over the past 5 sessions. The stock spiked 12.21% in intraday trading to $1.72 this Thursday, Apr 01, hitting a weekly high. The stock’s 5-day price performance is -6.21%, and it has moved by -13.22% in 30 days. Despite these dips, the overall price performance for the year is 21.77%. The short interest in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is 8.09 Million shares and it means that shorts have 1.28 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.21, which implies an increase of 245.03% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $0.83 and $9 respectively. As a result, ACRX is trading at a discount of 496.03% off the target high and -45.03% off the low.
AcelRx Pharmaceuticals, Inc. (ACRX) projections and forecasts
Revenue for the current quarter is expected to be $990Million as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $1.56 Million by the end of June 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $386Million and $2.02 Million respectively. In this case, analysts expect current quarter sales to grow by 156.5% and then fell by -22.8% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 3%. While earnings are projected to return 29.6% in 2021, the next five years will return 0% per annum.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)’s Biggest Investors
AcelRx Pharmaceuticals, Inc. insiders own 2.04% of total outstanding shares while institutional holders control 24.71%, with the float percentage being 25.22%. Blackrock Inc. is the largest shareholder of the company, while 108 institutions own stock in it. As of Dec 30, 2020, the company held over 5.64 Million shares (or 4.74% of all shares), a total value of $6.99 Million in shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The next largest institutional holding, with 3.98 Million shares, is of Vanguard Group, Inc. (The)’s that is approximately 3.34% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $4.93 Million.
Also, the Mutual Funds coming in first place with the largest holdings of AcelRx Pharmaceuticals, Inc. (ACRX) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2020 indicates that Vanguard Total Stock Market Index Fund owns about 2,434,573 shares. This amounts to just over 2.05 percent of the company’s overall shares, with a $3.02 Million market value. The same data shows that the other fund manager holds slightly less at 1.88 Million, or about 1.58% of the stock, which is worth about $3.54 Million.